Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042706 | 0.91 | ADRB1 (0.71) | ADRB3ADRB1MAPTLMNAADRB2 | |
| SCHEMBL7039822 | 0.91 | ADRB3 (0.74) | ADRB3ADRB1MAPTADRB2CYP2D6 | |
| SCHEMBL7041956 | 0.88 | ADRB3 (0.67) | ADRB3ADRB1MAPTADRB2CYP2D6 | |
| SCHEMBL7041981 | 0.88 | ADRB3 (0.70) | ADRB3ADRB1LMNAADRB2CYP2D6 | |
| SCHEMBL6538997 | 0.87 | ADRB3 (0.82) | ADRB3ADRB1MAPTADRB2CYP2D6 | |
| SCHEMBL9685359 | 0.86 | ADRB3 (0.64) | ADRB3ADRB1ABCB1MAPTLMNA | |
| SCHEMBL9685355 | 0.86 | ADRB3 (0.64) | ADRB3ADRB1ABCB1MAPTLMNA | |
| SCHEMBL7041978 | 0.86 | ADRB3 (0.74) | ADRB3ADRB1LMNAADRB2CYP2D6 | |
| SCHEMBL7044140 | 0.86 | ADRB3 (0.73) | ADRB3ADRB1MAPTADRB2CYP2D6 | |
| SCHEMBL6478914 | 0.84 | ADRB3 (0.71) | ADRB3ADRB1MAPTADRB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1292564-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001062705-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | XDH, ADH1A, ADRB1 | ADRB3 20/4885ADRB1 3/4885ABCB1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.